

SED-CARE TEMP-CARE MAP-CARE



<u>Sedation Temperature and Pressure after Cardiac</u> <u>Arrest and Re</u>suscitation



CONSENT, DATA ENTRY, eCRF & REMOTE MONITORING

Frances Bass: ICU Research Manager (RNSH) & Senior Project Manager (TGI), Australia

Dr Josef Dankiewicz: Cardiologist, Lund















Informed Consent Model

Consent from participant <u>PRIOR</u> to randomisation will <u>NOT</u> be possible

Consent from Legally Authorised Representative (LAR), Person Responsible (PR)/ Substitute Decision Maker (SDM)/Medial Treatment Decision Maker (MTDM) <u>PRIOR</u> to randomisation

Whenever possible consent will be obtained from a LAR/PR/SDM/MTDM prior to randomisation

Inclusion without prior consent with option to continue or withdraw

 Patients enrolled into the trial without prior consent, the participant or LAH/PR/SDM/MTDM informed about participation in study as soon as possible and given the option of <u>consent to continue</u> in the trial, or to <u>withdraw</u> from the trial





Who Obtains Consent?

- ICH-GCP: investigator's responsibility
- The investigator, or a person designated by the investigator, should fully inform the patient or LAR
- Investigator or designee (Co-PI, Sub-PI, RC.)
- Qualified, trained on the study protocol, consenting
- Comply with local ethical and regulatory requirement
- Any person obtaining consent throughout the study must be listed on the Site Signature & Delegation Log



How should consent be administered?

- Timing: before participation
- Environment: private, confidential dialogue can take place
- Fully inform all pertinent aspects of the trial
 - Orally and EC approved information sheet
- Non-technical and practical language
- Do no use language
 - to coerce or unduly influence to participate
 - that causes/appears to waive any legal rights or appear to release the investigator, institution, sponsor or their agents from liability for negligence
- Provide ample time and opportunity to inquire about the details of the trial and answer questions







What information should be provided to participants?

- Voluntary, can refuse, withdraw anytime
- Access to participant original medical records for verification, ensuring confidentiality, by monitors, auditor, ECs and reg. authorities
- Participants identify will be kept confidentiality
- If new information becomes available that is relevant to participation it will be provided in a timely manner
- Payments for participation, expenses to the participant







What information should be provided to participants?

- Contact details
 - for further information and the rights of the participant
 - event of trial-related injury
- Circumstances and/or reasons under which the subject's participation in the trial may be terminated
- Expected duration of participation in the trial
- Approximate number of participants involved in the trial







Consent Documentation

- The Participant or LAR/PR/SDM/MTDM and the person obtaining consent <u>must</u> sign and date the consent form
- All signed forms must be retained for 15 years
- Original signed consent form (and information sheet) is kept with the study file,
 - One full copy filed in patient's medical records
 - One full copy given to patient/PR/SDM/MTDM
- The consent process should be documented in the patient's medical record
- All consents will be reviewed at Site Monitoring Visits





Withdrawal of Consent

- The participant and/or their LAR/PR/SDM/MTDM may withdraw their consent to participate in the study at any time
- Please seek permission (with discretion) to
 - o use <u>all</u> trial data
 - use trial data collected up to date of withdrawal
 - o access medical record to obtain health information
 - contact participant at 30-days, 6 and 12-months to obtain health information
 - complete follow-up questionnaires by telephone or face-to-face visit to obtain health information
- Complete the "Participant Withdrawal of Participation" found on the last page of the Information Sheet and Consent Form
- Document in the patient's medical records and study file













Data Collection

- Data collected up to 12 months post-enrolment, or to death (whichever occurs first)
- eCRF built using Spinnaker
- Keep your login ID and password information confidential
- All data definitions and explanations are explained thoroughly within the database by selecting the information button
- There is not a separate data dictionary or study completion manual



Database & eCRF



https://stepcare.spinnakersoftware.com



() stepcare



















Database Home Page

ticipants Sci

Pa

Stepcare

Screening log

Manage Monitoring

Andromeda Infirm... 👤 👻

2+ Add participant

Resources

14 Participants randomised at 997 - Andromeda Infirmary

Participant Study Number			r 📘	Find part	icipant	
	Participant	Age	Sex	Initials	Day	Randomised
	9970014	25	Male	TAB	45	11-Apr-2024
	9970013	25	Male	ABCD	46	10-Apr-2024
	9970012	58	Male	JTU	108	08-Feb-2024
	9970011		Male		206	02-Nov-2023
	9970010	36	Male	JUO	220	19-Oct-2023
	9970009	44	Male	ATT	223	16-Oct-2023
	9970008	56	Female	LOP	243	26-Sep-2023
	9970007	47	Female	EEN	250	19-Sep-2023
	9970006	39	Female		256	14-Sep-2023
	9970005	39	Male	RRR	256	13-Sep-2023
	9970004	59	Male	DGU	256	13-Sep-2023
	9970003	23	Male	NNN	270	30-Aug-2023
	9970002	19	Male	HJK	283	17-Aug-2023
	9970001	34	Male	MOB	293	07-Aug-2023

Alerts at 997 - Andromeda Infirmary

Reports







Randomising & Screening Patients

StepCare Participants Screening log Resources Manage Mor

Monitoring Reports

Alerts at 997 - Andromeda Infirmary

Andromeda Infirm... 👤 🔻

L+ Add participant

14 Participants randomised at 997 - Andromeda Infirmary

Participant Study	Numbe	r 📘	Find part	ticipant	
Participant	Age	Sex	Initials	Day	Randomised
9970014	25	Male	TAB	45	11-Apr-2024
9970013	25	Male	ABCD	46	10-Apr-2024
9970012	58	Male	JTU	108	08-Feb-2024
9970011		Male		206	02-Nov-2023
9970010	36	Male	JUO	220	19-Oct-2023
9970009	44	Male	ATT	223	16-Oct-2023
9970008	56	Female	LOP	243	26-Sep-2023
9970007	47	Female	EEN	250	19-Sep-2023
9970006	39	Female		256	14-Sep-2023
9970005	39	Male	RRR	256	13-Sep-2023
9970004	59	Male	DGU	256	13-Sep-2023
9970003	23	Male	NNN	270	30-Aug-2023
9970002	19	Male	HJK	283	17-Aug-2023
9970001	34	Male	MOB	293	07-Aug-2023







Next **Cancel**





Patient details

Eligibility criteria

Eligibility criteria

In-hospital

Arrest location 🕕

Out-of-hospital is defined as a patient not currently admitted in the hospital

Out-of-hospital

Arrest Cause 🗊

Please select the most probable cause of arrest as judged at the time of randomisation. If VT/VF and no other information choose arrhythmia not related to acute ischemia.

Cardiac	Non-cardiac Trauma/E		leeding	Intracranial bleed	
Unconscious i Is the patient unconscious or intuba	ated and sedated due to agitation		Yes	No	
Is the patient eligible for intens	sive care without restrictions o	r limitations 🕕	Yes	No	
ls the patient on ECMO 🕕			Yes	No	
ls the patient pregnant 🕕			Yes	No	
Previously randomised in the S	TEPCARE trial		Yes	No	
Next <u>Cancel</u>					





Patient details

Eligibility criteria

Best Interests

Consent

H lity	Consent Are all local consent requirements met i Yes No
FS	Perceived prognosis - for research purposes
	Does not impact randomisation and patient care
	Do you (physician randomising or physician in-charge) think this patient will have a good neurological outcome in 6 months
	••• O Yes - I, the physician randomising or physician in-charge, think this patient will have a good neurological outcome in 6 months
	O No - I, the physician randomising or physician in-charge, do not think this patient will have a good neurological outcome in 6 months
	OI am not a physician and the physician in charge is not available to answer this question right now
	Next <u>Cancel</u>







Randomising a Patient



Patient Summary



Patient Summary

Østep care	Participants Screening	log Resources	Manage	Monitorin	g Report	ts	Andro	omeda Infirm
	Find Participant Eligibility							
9970014 Randomised 11-Apr-2024 10:59	Participant 997001 Locked status: Open 🗹 Monitoring status: Not Participant 997001 Randomised	Monitored 🗹	9	No P	<u>SAE +</u> o uSAE rotocol de o protocol d	leviations		
✓ Summary					hange Log able	g Type	Date	User
✓ Randomisation	Initials	ТАВ			lourlyObs	Insert	<u>23 May</u>	Frances Bass
? Consent	Date of birth	17-Feb-1999			Consent	<u>Insert</u>	24 April	Josef Dankiewicz
? Key Baseline	Age at randomisation	25		E	<u>lourlyObs</u>	<u>Insert</u>	<u>16 April</u>	<u>Anna Tippett</u>
X Baseline	Sex at birth	Male			<u>CeyBaseline</u>	<u>Insert</u>	<u>11 April</u>	<u>Anna Tippett</u>
? Hourly Observations	ROSC	11-Apr-2024 08:00)		more chang	<u>ges</u>		
X Neuroprognostication								
X Interventions	Notes							
X Discharge								
X Vital Status								
X Day 30	Edit participant							
X Complications								



Hourly Observations

Stepcar	Participants	Screening lo	g Reso	ources Manag	ge Monitori	ng R	eports	Andromeda Infirm 👤 🦷
	Find Participant	Eligibility						
9970014	Enter the dat		r where da			n the clos	sest time	where they were available (if there are no new
Randomised 11-Apr-2024 10:59	End of	hour Time	Date	Measurements	Temperature	MAP	RASS	
10.55	X <u>0</u>	<u>11 am</u>	<u>11 Apr</u>					
	X <u>2</u>	<u>1 pm</u>	<u>11 Apr</u>					
✓ Summary	X <u>4</u>	<u>3 pm</u>	<u>11 Apr</u>					
✓ Randomisation	X <u>6</u>	<u>5 pm</u>	<u>11 Apr</u>					
? Consent	? <u>8</u>	<u>7 pm</u>	<u>11 Apr</u>	\checkmark	<u>ND</u>	<u>78.0</u>		
? Key Baseline	X <u>12</u>	<u>11 pm</u>	<u>11 Apr</u>					
X Baseline	X <u>14</u>	<u>1 am</u>	<u>12 Apr</u>					
? Hourly Observations	X <u>16</u>	<u>3 am</u>	<u>12 Apr</u>					
-	X <u>18</u>	<u>5 am</u>	<u>12 Apr</u>					
X Neuroprognostication	X <u>20</u>	<u>7 am</u>	<u>12 Apr</u>					
X Interventions	X <u>22</u>	<u>9 am</u>	<u>12 Apr</u>					
X Discharge	X <u>24</u>	<u>11 am</u>	<u>12 Apr</u>					
🗙 Vital Status	X <u>28</u>	<u>3 pm</u>	<u>12 Apr</u>					
X Day 30	X <u>32</u>	<u>7 pm</u>	<u>12 Apr</u>					
X Complications	X <u>36</u>	<u>11 pm</u>	<u>12 Apr</u>					
	X <u>40</u>	<u>3 am</u>	<u>13 Apr</u>					
	X <u>48</u>	<u>11 am</u>	<u>13 Apr</u>					
	X <u>56</u>	<u>7 pm</u>	<u>13 Apr</u>					
	X <u>72</u>	<u>11 am</u>	<u>14 Apr</u>					
	X <u>96</u>	<u>11 am</u>	<u>15 Apr</u>					
	<u>? 120</u>	<u>11 am</u>	<u> 16 Apr</u>	1				

Protocol Deviations

- Tyes of Protocol Deviation's
 - Enrolment of ineligible patient
 - Failure to comply with allocated temperature management strategy
 - Failure to comply with allocated blood pressure management strategy
 - Failure to comply with allocated sedation management strategy
 - o Other
- Document one Protocol Deviation per PD form
- Enter Protocol Deviation CRF onto the database ASAP
- Describe the deviation and corrective action taken



 \Box



Protocol Deviations



✓ Summary

Participant 9970009

Locked status: Open

Monitoring status: Not Monitored

Participant 9970009

Randomised

16-Oct-2023 13:48





Participant 9970009

Locked status: Open

Monitoring status: Not Monitored

Participant 9970009

Randomised

16-Oct-2023 13:48







Protocol Deviations

Protocol Deviation for participant 9970009

Nature of protocol d	eviation		
Date and time of deviation 🕚	dd-MMM-уууу	:	24 Hour clock

Type of deviation:

Enrolment of ineligible patient

□ Failure to comply with allocated temperature management strategy for reasons not permitted in the protocol

□ Failure to comply with allocated blood pressure management strategy for reasons not permitted in the protocol

□ Failure to comply with allocated sedation management strategy for reasons not permitted in the protocol

Other

Please describe the deviation:

Please describe any corrective actions that were taken in reaction to the protocol deviation:



Complications – Safety Events

() stepcare	Participants Screening log Resources Manage Monitoring Reports Andromeda Infirm						
	Find Participant Eligibility						
9970012 Randomised 08-Feb-2024 09:26	Complications patient 9970012 Infectious Complications in the ICU Did the patient develop sepsis According to Sepsis III definition						
✓ Summary	Did the patient develop pneumonia 🚯 Yes No						
✓ Randomisation	Bleeding						
X Consent	Did the patient experience bleeding 🕕 None Mild Moderate Severe						
X Key Baseline							
Baseline	Arrhythmic Complications in the ICU						
Hourly Observations	Did the patient have a recurrent cardiac arrest (defibrillation or chest compressions) Yes No						
X Neuroprognostication	Other arrhythmia requiring cardioversion, an anti-arrhythmic drug, or temporary pacing Yes No						
(Interventions							
Discharge	Venous thromboembolism in the ICU						
🗙 Vital Status	Deep Vein Thrombosis (DVT) or Pulmonary Embolism in the ICU 🕕 🛛 Yes 🛛 No						
X Day 30							
Complications	Ischemic complication						
	Mesenteric ischemia 🕕 Yes No						
	Limb ischemia 🕕 Yes No						
	Digital necrosis 🕕 Yes No						
	Sedation Complications						
	Unplanned extubation Yes No						

Unexpected Serious Adverse Events





Unexpected Serious Adverse Events

uSAE for participant 9970009

Unexpected serious adverse event

Has there been an unexpected serious adverse event that:

No

Yes

- caused death or
- was life threatening or
- may result in significant disability
- AND
- which is NOT expected in a critical ill patient





Unexpected Serious Adverse Events

uSAE for participant 9970009

Unexpected serious adverse event







eCRF test accounts

Test site: https://stepcare-stage.spinnakersoftware.com/

Password: cardiacarrest

User name: Choose the location below corresponding to your time zone.

For investigators and nurses

United Kingdom, Ireland (UTC +00.00) User name: STEPCAREtest_UK

Sweden, Belgium, Italy, Luxembourg, Norway, Switzerland (UTC +01.00) User name: STEPCAREtest_SE

Finland, Czech Republic (UTC +02.00) User name: STEPCAREtest_FI

Saudia Arabia, Kuwait (UTC +03.00) User name: STEPCAREtest_SA

Singapore (UTC +08.00) User name: STEPCAREtest_SG

Australia (UTC +10.00) User name: STEPCAREtest_AU





Safety reporting

- Safety events will be reported during the intensive care unit stay only
- Safety events should be reported within 24 hours from awareness of the event
- The specific safety events will be reported whether they are considered related to the intervention or not
- The relatedness between the trial interventions and the unexpected serious complications should be determined by the local investigator



eCRF feedback

Stepcare Participants

Resources Manage

Screening log

Monitoring Reports

Andromeda Infirm...

τ....

Find Participant Participant 9970014 uSAE + 9 Ξ No uSAE Locked status: Open 🗹 9970014 Monitoring status: Not Monitored 🗹 Randomised 11-Apr-2024 Protocol deviations + 10:59 No protocol deviations Participant 9970014 11-Apr-2024 10:59 Randomised Change Log ✓ Summary Table Туре Date User ✓ Randomisation TAB Initials **HourlyObs** <u>23 May</u> Frances Bass ? Consent 17-Feb-1999 24 April Consent Insert Josef Dankiewicz Date of birth **HourlyObs** Anna Tippett ? Key Baseline 25 Insert 16 April Age at randomisation <u>KeyBaseline</u> Insert 11 April Anna Tippett X Baseline Male Sex at birth ... more changes ? Hourly Observations 11-Apr-2024 08:00 ROSC X Neuroprognostication X Interventions Notes X Discharge X Vital Status X Day 30 X Complications

fbass@georgeinstitute.org.au







Status Board

New In
 7





Group by: Status V Sort by: Date created V

Duplicate tickets 32
Matterhorm



D 3787599 ·













https://stepcare.org/



latabase Contact Search

About the study - News For patients Documents Substudies Clinics Partners FAQ

The STEPCARE (Sedation, TEmperature and Pressure after Cardiac Arrest and REsuscitation) trial

Program for the STEPCARE meeting in Helsingborg May 29th

23 May, 2024

The first STEPCARE-patient at Østfold Hospital Kalnes, Norway, is now included!

First randomization at Prince Charles Hospital 22 April, 2024





 \rightarrow



Documents



The George Institute



Monitoring

- The purpose of monitoring is to ensure that the clinical trial is conducted in accordance with the study protocol, GCP and any local regulatory requirements
- Early visits conducted to pick-up any consistent errors and to discuss issues (if any)





Remote Monitoring

Josef to discuss







Source Data Verification

- The purpose of SDV is to document the existence of the patient and substantiate integrity of the study data collected
- A source document is the first place something is recorded i.e. original documents, data and records
- Data collected should be from a source document which can be verified by a study monitor or local/national regulatory authorities.
- Examples of source documents include medical notes (electronic or paper), laboratory results, ambulance chart, ED charts, ward charts, OT charts and other hospital records
- A paper case report form is not a source document









